The price of G1 Therapeutics Inc (NASDAQ: GTHX) closed at $4.55 in the last session, down -2.78% from day before closing price of $4.68. On the day, 547845 shares were traded.
Ratios:
We take a closer look at GTHX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 1.62 whereas as Long-Term Debt/Eq ratio is at 1.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Umstead John W. V sold 6,547 shares for $3.02 per share. The transaction valued at 19,752 led to the insider holds 123,896 shares of the business.
Malik Rajesh sold 28,600 shares of GTHX for $132,143 on Feb 12 ’24. The Chief Medical Officer now owns 169,938 shares after completing the transaction at $4.62 per share. On Jan 04 ’24, another insider, MURDOCK TERRY L, who serves as the Chief Operating Officer of the company, sold 721 shares for $2.94 each. As a result, the insider received 2,121 and left with 103,638 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.88 while its Price-to-Book (P/B) ratio in mrq is 6.68.
Stock Price History:
Over the past 52 weeks, GTHX has reached a high of $5.00, while it has fallen to a 52-week low of $1.08.
Shares Statistics:
A total of 51.93M shares are outstanding, with a floating share count of 42.38M. Insiders hold about 18.81% of the company’s shares, while institutions hold 24.16% stake in the company.
Earnings Estimates
The company has G1 Therapeutics, Inc. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $69.90, with high estimates of $7.74 and low estimates of $9.50.
EPS for the following year is $Mutual Fund, with Stocks analysts recommending between $Mutual Fund and $Stocks.
